Rheumatology
Podcast | Childhood-Onset SLE
6 Apr, 2023 | 13:12h | UTC#77: Childhood-Onset SLE – Is It Sometimes Lupus? – The Cribsiders
RCT | No significant fracture reduction from monthly 60,000 IU vitamin D3 supplementation
4 Apr, 2023 | 13:58h | UTCThe effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
RCT | Supplemental Vitamin D does not reduce incident fractures in midlife and older adults.
RCT | Vitamin D supplementation shows no significant impact on psoriasis severity
4 Apr, 2023 | 13:51h | UTCSummary: In a randomized, double-blind, placebo-controlled clinical trial involving 122 participants with plaque psoriasis, researchers investigated the effects of vitamin D supplementation on psoriasis severity during winter. Participants received either vitamin D (cholecalciferol, 100,000 IU loading dose followed by 20,000 IU/week) or a placebo for four months. The primary outcome was Psoriasis Area Severity Index (PASI) scores, with secondary outcomes including Physician Global Assessment, self-administered PASI, and Dermatology Life Quality Index scores.
The study found no significant difference in PASI scores or secondary outcomes between the two groups. The results suggest that vitamin D supplementation does not affect psoriasis severity. However, low baseline severity scores and a lower than expected increase in 25-hydroxyvitamin D levels in the intervention group may have influenced the findings, indicating that further research may be needed to account for these factors.
Article: Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
This RCT, performed in North-Norway, found no measurable effect of vitamin D supplementation on psoriasis severity during winter. Low baseline severity, & lower-than-expected rise in 25(OH)D levels in intervention group, may have affected the results. https://t.co/ip17uFQsgM
— JAMA Dermatology (@JAMADerm) March 29, 2023
2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults
30 Mar, 2023 | 14:14h | UTCVitamin D supplementation and cognition—Results from analyses of the D-Health trial – Journal of the American Geriatrics Society (link to abstract – $ for full-text)
Related:
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Research: Circulating vitamin D concentration and risk of seven cancers
Research: Vitamin D and risk of total and site specific cancers
RCT | Hydroxychloroquine in children with proliferative lupus nephritis
30 Mar, 2023 | 14:11h | UTC
SR | Extracutaneous features and complications of the Ehlers-Danlos syndromes
30 Mar, 2023 | 13:41h | UTC
M-A | Limited evidence for analgesic effectiveness in acute low back pain treatment
29 Mar, 2023 | 13:32h | UTCSummary: The objective of this systematic review and network meta-analysis was to assess the effectiveness and safety of various analgesic medicines for treating acute non-specific low back pain. After examining 98 randomized controlled trials with over 15,000 participants, the study found that the quality of evidence for the effectiveness and safety of these medications is low or very low.
Some analgesic medicines showed potential in reducing pain intensity, but the evidence was limited due to trial risk of bias and imprecision in effect estimates. Furthermore, certain medications might increase the risk of adverse events during treatment, with evidence ranging from moderate to very low confidence.
Given the lack of high-quality evidence, clinicians and patients are advised to be cautious when using analgesic medicines for acute non-specific low back pain. More robust head-to-head comparison trials are needed to provide clearer guidance on the best course of treatment.
News Release: Study finds “considerable uncertainty” around effectiveness and safety of analgesics for low back pain – BMJ Newsroom
Commentary from the author on Twitter (thread – click for more)
Out today in @bmj_latest.
We found “considerable uncertainty” around the effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain.
Available at https://t.co/PeOmEOeJyJ
Thread ? pic.twitter.com/T8YDNGhhME
— Michael Wewege (@mawewege) March 22, 2023
Cohort Study | Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated
29 Mar, 2023 | 13:02h | UTC
SR | Local corticosteroid injection versus placebo for carpal tunnel syndrome
29 Mar, 2023 | 13:00h | UTCLocal corticosteroid injection versus placebo for carpal tunnel syndrome – Cochrane Library
Summary: Local steroid injection for carpal tunnel syndrome – Cochrane Library
Commentary on Twitter
Local steroid injection for #CarpalTunnel syndrome @CochraneNMD systematic review looks at the evidence from 9 studies involving 639 people.
'Probably improves symptoms & function for up to six months.'
Read the full @CochraneLibrary review: https://t.co/4z5euxpQqE pic.twitter.com/VEy0VUNxV8
— Cochrane UK (@CochraneUK) February 4, 2023
RCT | Rituximab is superior to azathioprine for maintenance of remission for patients with ANCA vasculitis and relapsing disease
27 Mar, 2023 | 12:57h | UTC
Consensus Paper | Connective tissue disease-associated pulmonary arterial hypertension
24 Mar, 2023 | 13:06h | UTC
M-A | Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease
24 Mar, 2023 | 13:02h | UTC
EULAR recommendations for the management of ANCA-associated vasculitis
20 Mar, 2023 | 13:47h | UTC
Cross-sectional study | Impact of different alcoholic beverages on serum urate levels
20 Mar, 2023 | 13:16h | UTC
Commentary on Twitter
Beer and wine was associated with high and moderate increases in serum urate levels, respectively; sake was associated with a modest increase in serum urate levels, in patients getting routine checkups in Japan. https://t.co/J8OqKJI9fQ
— JAMA Network Open (@JAMANetworkOpen) March 17, 2023
SR | Splinting for carpal tunnel syndrome
17 Mar, 2023 | 12:57h | UTCSplinting for carpal tunnel syndrome – Cochrane Library
Summary: Splinting for carpal tunnel syndrome – Cochrane Library
M-A | Maternal and infant outcomes of pregnancy associated with anti-SSA/RO antibodies
16 Mar, 2023 | 13:15h | UTC
RCT | Intra-articular 10 mg triamcinolone acetonide non-inferior to 40 mg for knee osteoarthritis pain relief
16 Mar, 2023 | 12:55h | UTC
Review | MRI image features with an evident relation to low back pain
15 Mar, 2023 | 15:01h | UTC
Review | Treatment of systemic sclerosis
9 Mar, 2023 | 14:05h | UTCState-of-the-art evidence in the treatment of systemic sclerosis – Nature Reviews Rheumatology
Cohort Study | Early pregnancy exposure to NSAIDs is associated with slightly higher risks of neonatal and maternal adverse outcomes
7 Mar, 2023 | 12:56h | UTCSummary:
A nationwide cohort study in South Korea, including 1.8 million pregnancies, investigated the association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during early pregnancy and neonatal and maternal adverse outcomes.
The study revealed that pregnant women exposed to NSAIDs during early pregnancy were at increased risk of oligohydramnios and had a slightly higher likelihood of having an infant with major congenital malformations and low birth weight. These risks remained elevated when comparing NSAIDs against acetaminophen or past users.
The study suggests that clinicians should weigh the need to prescribe NSAIDs in early pregnancy against the modest but possible risk of neonatal and maternal outcomes and consider prescribing nonselective NSAIDs for <10 days, with continued careful monitoring for any safety signals.
RCT | Baricitinib vs. placebo for systemic lupus erythematosus
3 Mar, 2023 | 13:39h | UTCBaricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) – The Lancet (link to abstract – $ for full-text)
See also: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
NEW in @TheLancet—Two phase 3 trials of #baricitinib for systemic #lupus erythematosus #SLE-BRAVE-I > https://t.co/wX0w7w4Glm
SLE-BRAVE-II > https://t.co/56sd0DmjN9
Linked Comment by Laura Durcan (@Rheum2improve) & Grainne Murphy > https://t.co/RBJYEcSNle pic.twitter.com/XW6sXQnSn9
— The Lancet Rheumatology (@TheLancetRheum) February 27, 2023
Cohort Study | Risk factors for serious infections in ANCA-associated vasculitis
2 Mar, 2023 | 12:52h | UTCRisk factors for serious infections in ANCA-associated vasculitis – Annals of the Rheumatic Diseases
Commentary from the author on Twitter
Just published in @ARD_BMJ (https://t.co/mZVZ7HZaLC) – risk of severe infections in #AAV. The prophylactic use of low-dose TMP/SMX may reduce this risk. A work I am really proud of. Many thanks to all my co-authors, especially to my friend @AKronbichler for his endless support!
— Balazs Odler (@odlerb) January 26, 2023
Chronic low back pain: a narrative review of recent international guidelines for diagnosis and conservative treatment
27 Feb, 2023 | 12:46h | UTC
M-A | Pregnancy outcomes in Takayasu arteritis patients
24 Feb, 2023 | 13:40h | UTCSummary: The systematic review and meta-analysis examined the data from 27 studies with 825 pregnancies and found that pregnant women with Takayasu arteritis (TA) are at higher risk for adverse pregnancy outcomes; 37% developed hypertension, 14% developed pre-eclampsia, and the occurrence of miscarriage was 16%. High disease activity during pregnancy, renal artery involvement, and history of hypertension were identified as risk factors, while maternal age or prolonged disease duration did not pose a risk. The most common treatments were corticosteroids, anti-hypertensive agents, low-dose aspirin, and azathioprine. The study was limited by the heterogeneity of the included studies and the lack of large-scale prospective case-control studies, indicating the need for further research.
Guideline | Exercise-based knee and anterior cruciate ligament injury prevention
15 Feb, 2023 | 16:02h | UTC